Skip to main content

Revolution Medicines, Inc.

RVMDW
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001628171

In the last 90 days, Revolution Medicines, Inc. insiders filed 0 open-market purchases and 17 sales; 22 institutions reported holding it in 13F filings for Q2 2026, worth $93.0M in total; no superinvestor holds it.

Other share classesRVMD

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Revolution Medicines, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
17 filings
10 insiders, $77.6M in total
Insiders trading
10
Net value
−$77.6M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Revolution Medicines, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Revolution Medicines, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Mancini AnthonySee Remarks39,765Sep 28, 20268
Anderson Elizabeth MDirector4,333Sep 24, 20263
Sandler Alan B.Chief Development Officer52,868Sep 18, 20261
Kelsey Stephen MichaelSee Remarks286,307Sep 18, 20267
Horn Margaret AChief Operating Officer149,680Sep 18, 20267
Goldsmith Mark ASee Remarks253,342Sep 18, 202613
Cislini JeffSVP & General Counsel52,541Sep 18, 20269
Anders JackChief Financial Officer119,216Sep 18, 20269
Kim Lorence H.Director0IndirectSep 10, 20263
Patel SushilDirector21,656Jul 1, 20262
Borisy AlexisDirector2,340,075Jun 23, 20261
Horning SandraDirector97,765Jun 23, 20261
Clyburn FrankDirector10,929Jun 23, 20261
Borellini FlaviaDirector26,215Jun 23, 20261
Wang XiaolinSee Remarks116,063Mar 19, 20262
Wei LinChief Medical Officer101,366Mar 19, 20262
Schroeder ThiloDirector760,869IndirectDec 9, 20240
Weber BarbaraDirector13,065Oct 10, 20240
Schmidt Eric ThomasDirector21,251Jun 12, 20230
Exter NeilDirector28,815Jun 17, 20220
Tepper Robert I10% Owner5,104,130Jun 10, 20220
Third Rock Ventures III, L.P.10% Owner5,104,130Jun 10, 20220
TRV GP III, LLC10% Owner5,104,130Jun 10, 20220
Third Rock Ventures GP III, L.P.10% Owner5,104,130Jun 10, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 20, 2025 (view filing)Nov 182 daysGoldsmith Mark ASee RemarksSSale−20.0K$70.38−$1.41M−7.5%247.9K after10b5-1
Nov 20, 2025 (view filing)Nov 182 daysCislini JeffGeneral CounselSSale−13.4K$70.14−$939.0K−21.0%50.4K after10b5-1
Nov 14, 2025 (view filing)Nov 122 daysGoldsmith Mark ASee RemarksSSale−20.0K$65.07−$1.30M−7.5%247.9K after10b5-1
Nov 13, 2025 (view filing)Nov 112 daysAnders JackChief Financial OfficerSSale−10.0K$64.00−$640.0K−8.3%111.0K after10b5-1
Nov 12, 2025 (view filing)Nov 75 daysGoldsmith Mark ASee RemarksSSale−30.0K$60.31−$1.81M−7.9%347.9K after10b5-1
Oct 20, 2025 (view filing)Oct 173 daysCislini JeffGeneral CounselSSale−12.0K$55.00−$660.0K−19.2%50.4K after10b5-1
Oct 20, 2025 (view filing)Oct 16-174 daysGoldsmith Mark ASee RemarksSSale−20.0K$52.74−$1.05M−4.2%452.3K after2 lots10b5-1
Oct 15, 2025 (view filing)Oct 132 daysKelsey Stephen MichaelSee RemarksSSale−25.0K$48.54−$1.21M−8.1%284.0K after10b5-1
Sep 26, 2025 (view filing)Sep 242 daysCislini JeffGeneral CounselSSale−1.80K$44.26−$79.6K−3.4%50.4K after10b5-1
Sep 18, 2025 (view filing)Sep 162 daysWei LinChief Medical OfficerSSale−2.16K$45.82−$99.0K−2.4%88.3K after10b5-1
Sep 18, 2025 (view filing)Sep 162 daysKelsey Stephen MichaelSee RemarksSSale−5.37K$45.82−$245.9K−1.9%284.0K after10b5-1
Sep 18, 2025 (view filing)Sep 162 daysGoldsmith Mark ASee RemarksSSale−13.4K$45.82−$614.5K−2.9%452.3K after10b5-1
Sep 18, 2025 (view filing)Sep 162 daysHorn Margaret AChief Operating OfficerSSale−4.78K$45.82−$218.8K−3.2%145.9K after10b5-1
Sep 18, 2025 (view filing)Sep 162 daysCislini JeffGeneral CounselSSale−1.87K$45.82−$85.6K−3.5%52.2K after10b5-1
Sep 18, 2025 (view filing)Sep 162 daysAnders JackChief Financial OfficerSSale−2.32K$45.82−$106.3K−2.0%111.0K after10b5-1
Sep 15, 2025 (view filing)Sep 11-154 daysKelsey Stephen MichaelSee RemarksSSale−125.0K$44.46−$5.56M−30.2%289.4K after4 lots10b5-1
Sep 4, 2025 (view filing)Sep 2-32 daysAnders JackChief Financial OfficerSSale−10.0K$40.10−$401.0K−8.1%113.3K after2 lots10b5-1
Jun 23, 2025 (view filing)Jun 203 daysCislini JeffGeneral CounselSSale−1.91K$39.61−$75.7K−3.4%54.1K after10b5-1
Jun 18, 2025 (view filing)Jun 162 daysHorn Margaret AChief Operating OfficerSSale−3.51K$39.83−$139.8K−2.3%150.7K after10b5-1
Jun 18, 2025 (view filing)Jun 162 daysGoldsmith Mark ASee RemarksSSale−13.5K$39.83−$537.5K−3.1%428.7K after10b5-1
Jun 18, 2025 (view filing)Jun 162 daysCislini JeffGeneral CounselSSale−1.88K$39.83−$74.8K−3.2%56.0K after10b5-1
Jun 18, 2025 (view filing)Jun 162 daysAnders JackChief Financial OfficerSSale−2.17K$39.83−$86.4K−1.9%113.3K after10b5-1
Jun 18, 2025 (view filing)Jun 162 daysKelsey Stephen MichaelSee RemarksSSale−4.29K$39.83−$170.8K−1.5%289.4K after10b5-1
Jun 18, 2025 (view filing)Jun 162 daysWei LinChief Medical OfficerSSale−2.17K$39.83−$86.6K−2.3%90.5K after10b5-1
Mar 24, 2025 (view filing)Mar 204 daysCislini JeffGeneral CounselSSale−2.04K$38.71−$79.0K−3.4%57.7K after10b5-1
Mar 19, 2025 (view filing)Mar 172 daysCislini JeffGeneral CounselSSale−1.46K$39.04−$56.9K−2.4%59.8K after10b5-1
Mar 19, 2025 (view filing)Mar 172 daysGoldsmith Mark ASee RemarksSSale−11.7K$39.04−$458.3K−2.6%441.6K after10b5-1
Mar 19, 2025 (view filing)Mar 172 daysAnders JackChief Financial OfficerSSale−1.86K$39.04−$72.8K−1.6%115.0K after10b5-1
Mar 19, 2025 (view filing)Mar 172 daysHorn Margaret AChief Operating OfficerSSale−3.06K$39.04−$119.4K−2.0%153.5K after10b5-1
Mar 19, 2025 (view filing)Mar 172 daysKelsey Stephen MichaelSee RemarksSSale−3.29K$39.04−$128.6K−1.1%293.1K after10b5-1
Jan 22, 2025 (view filing)Jan 211 dayCislini JeffGeneral CounselSSale−2.41K$40.50−$97.4K−5.8%39.2K after10b5-1
Dec 18, 2024 (view filing)Dec 162 daysHorn Margaret AChief Operating OfficerSSale−4.33K$45.40−$196.5K−3.3%128.0K after10b5-1
Dec 18, 2024 (view filing)Dec 162 daysGoldsmith Mark ASee RemarksSSale−11.7K$45.40−$531.8K−3.5%325.1K after10b5-1
Dec 18, 2024 (view filing)Dec 162 daysKelsey Stephen MichaelSee RemarksSSale−4.66K$45.40−$211.7K−1.8%259.7K after10b5-1
Dec 18, 2024 (view filing)Dec 162 daysCislini JeffGeneral CounselSSale−1.60K$45.40−$72.6K−3.7%41.6K after10b5-1
Dec 18, 2024 (view filing)Dec 162 daysAnders JackChief Financial OfficerSSale−2.63K$45.40−$119.6K−2.7%96.5K after10b5-1
Dec 9, 2024 (view filing)Dec 54 daysSchroeder ThiloDirectorPPurchase+1.30M$46.00+$60.0MNew position760.9K after2 lots
Nov 19, 2024 (view filing)Nov 154 daysCislini JeffGeneral CounselSSale−2.55K$55.13−$140.8K−5.6%43.1K after10b5-1
Nov 15, 2024 (view filing)Nov 132 daysKelsey Stephen MichaelSee RemarksSSale−16.7K$58.66−$977.6K−5.9%264.4K after2 lots10b5-1
Nov 8, 2024 (view filing)Nov 62 daysCislini JeffGeneral CounselSSale−6.00K$60.00−$360.0K−11.6%45.6K after10b5-1
Nov 5, 2024 (view filing)4:21 PM ETNov 1-44 daysGoldsmith Mark ASee RemarksSSale−60.0K$55.48−$3.33M−16.7%300.2K after2 lots10b5-1
Nov 5, 2024 (view filing)4:21 PM ETNov 14 daysGoldsmith Mark ASee RemarksSSale−10.0K$55.02−$550.2K−32.9%20.4K after2 lots10b5-1
Nov 4, 2024 (view filing)Oct 314 daysPatel SushilDirectorSSale−5.00K$54.14−$270.7K−20.0%19.9K after10b5-1
Oct 16, 2024 (view filing)Oct 142 daysKelsey Stephen MichaelSee RemarksSSale−16.7K$49.49−$824.8K−5.9%264.4K after2 lots10b5-1
Oct 15, 2024 (view filing)Oct 114 daysHorn Margaret AChief Operating OfficerSSale−50.0K$50.34−$2.52M−27.4%132.3K after10b5-1
Oct 15, 2024 (view filing)Oct 114 daysGoldsmith Mark ASee RemarksSSale−30.0K$50.36−$1.51M−9.1%300.2K after10b5-1
Oct 15, 2024 (view filing)Oct 114 daysAnders JackChief Financial OfficerSSale−10.0K$50.30−$503.0K−9.2%98.9K after10b5-1
Oct 15, 2024 (view filing)Oct 114 daysCislini JeffGeneral CounselSSale−6.00K$50.17−$301.0K−11.6%45.6K after10b5-1
Oct 10, 2024 (view filing)Oct 82 daysWeber BarbaraDirectorSSale−5.20K$48.02−$249.7K−28.5%13.1K after10b5-1
Oct 3, 2024 (view filing)Oct 12 daysGoldsmith Mark ASee RemarksSSale−10.0K$44.93−$449.3K−3.2%300.2K after2 lots10b5-1